Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 334.35 billion. The enterprise value is 378.13 billion.
Market Cap | 334.35B |
Enterprise Value | 378.13B |
Important Dates
The next estimated earnings date is Wednesday, January 22, 2025.
Earnings Date | Jan 22, 2025 |
Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +9.21% |
Shares Change (QoQ) | +0.44% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 607.58M |
Valuation Ratios
The trailing PE ratio is 737.60.
PE Ratio | 737.60 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 8.96 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.19, with an EV/FCF ratio of -1,218.21.
EV / Earnings | 834.18 |
EV / Sales | 4.34 |
EV / EBITDA | 27.19 |
EV / EBIT | 57.71 |
EV / FCF | -1,218.21 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.61.
Current Ratio | 1.03 |
Quick Ratio | 0.43 |
Debt / Equity | 0.61 |
Debt / EBITDA | 3.61 |
Debt / FCF | -154.20 |
Interest Coverage | 1.36 |
Financial Efficiency
Return on equity (ROE) is 0.58% and return on invested capital (ROIC) is 2.95%.
Return on Equity (ROE) | 0.58% |
Return on Assets (ROA) | 2.46% |
Return on Capital (ROIC) | 2.95% |
Revenue Per Employee | 12.95M |
Profits Per Employee | 67,465 |
Employee Count | 6,719 |
Asset Turnover | 0.58 |
Inventory Turnover | 1.54 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +96.27% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +96.27% |
50-Day Moving Average | 253.25 |
200-Day Moving Average | 186.70 |
Relative Strength Index (RSI) | 47.08 |
Average Volume (20 Days) | 469,654 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 87.04 billion and earned 453.30 million in profits. Earnings per share was 0.34.
Revenue | 87.04B |
Gross Profit | 52.36B |
Operating Income | 5.90B |
Pretax Income | 3.22B |
Net Income | 453.30M |
EBITDA | 12.87B |
EBIT | 5.90B |
Earnings Per Share (EPS) | 0.34 |
Balance Sheet
The company has 4.08 billion in cash and 47.86 billion in debt, giving a net cash position of -43.78 billion.
Cash & Cash Equivalents | 4.08B |
Total Debt | 47.86B |
Net Cash | -43.78B |
Net Cash Per Share | n/a |
Equity (Book Value) | 79.07B |
Book Value Per Share | 59.51 |
Working Capital | 1.44B |
Cash Flow
In the last 12 months, operating cash flow was 6.81 billion and capital expenditures -7.12 billion, giving a free cash flow of -310.40 million.
Operating Cash Flow | 6.81B |
Capital Expenditures | -7.12B |
Free Cash Flow | -310.40M |
FCF Per Share | n/a |
Margins
Gross margin is 60.15%, with operating and profit margins of 6.77% and 0.52%.
Gross Margin | 60.15% |
Operating Margin | 6.77% |
Pretax Margin | 3.70% |
Profit Margin | 0.52% |
EBITDA Margin | 14.79% |
EBIT Margin | 6.77% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.11, which amounts to a dividend yield of 0.04%.
Dividend Per Share | 0.11 |
Dividend Yield | 0.04% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -9.21% |
Shareholder Yield | -9.17% |
Earnings Yield | 0.14% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |